Literature DB >> 8866624

Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine.

L H Lassen1, L L Thomsen, C Kruuse, H K Iversen, J Olesen.   

Abstract

It has previously been shown that in migraine sufferers infusion of glyceryl trinitrate (GTN) and histamine causes an immediate headache during the infusion and a genuine migraine attack one to several hours after the infusion. This identical time profile indicates a common mechanism of action. To evaluate whether GTN causes headache via liberation of histamine, we studied the effect of GTN 0.5 micrograms.kg-1.min-1 for 20 min in seven migraine sufferers, once after pretreatment with the histamine-1 (H1)-receptor blocker mepyramine (0.5 mg.kg-1) and once without pretreatment. This mepyramine dose is known to completely abolish histamine-induced headache. After pretreatment with mepyramine five patients experienced migraine, and without pretreatment six patients did so. The median peak headache score was 7 on a 0-10 scale with and without mepyramine pretreatment. The arterial responses, evaluated with transcranial Doppler, were also unaffected by the mepyramine pretreatment. Our results demonstrate that neither headache nor arterial dilatation due to GTN infusion is caused by histamine release. In all likelihood the common mediator of migraine induction by GTN and histamine is nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866624     DOI: 10.1007/bf00203773

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Experimental and biological variation of three-dimensional transcranial Doppler measurements.

Authors:  L L Thomsen; H K Iversen
Journal:  J Appl Physiol (1985)       Date:  1993-12

2.  Administration set suitable for use with intravenous nitroglycerin.

Authors:  D M Baaske; A H Amann; N N Karnatz; J Wong; D M Wagenknecht; J E Carter; R G Stoll
Journal:  Am J Hosp Pharm       Date:  1982-01

3.  Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics.

Authors:  Helle K Iversen; Jes Olesen; Peer Tfelt-Hansen
Journal:  Pain       Date:  1989-07       Impact factor: 6.961

4.  A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks.

Authors:  L L Thomsen; C Kruuse; H K Iversen; J Olesen
Journal:  Eur J Neurol       Date:  1994-09       Impact factor: 6.089

5.  Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT.

Authors:  A Dahl; D Russell; R Nyberg-Hansen; K Rootwelt
Journal:  Stroke       Date:  1989-12       Impact factor: 7.914

6.  Effect of histamine on regional cerebral blood flow in man.

Authors:  A A Krabbe; J Olesen
Journal:  Cephalalgia       Date:  1982-03       Impact factor: 6.292

7.  Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms.

Authors:  Annette Aebelholt Krabbe; Jes Olesen
Journal:  Pain       Date:  1980-04       Impact factor: 6.961

8.  Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine.

Authors:  L H Lassen; L L Thomsen; J Olesen
Journal:  Neuroreport       Date:  1995-07-31       Impact factor: 1.837

9.  Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide.

Authors:  H K Iversen; J Olesen
Journal:  Cephalalgia       Date:  1994-12       Impact factor: 6.292

10.  Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers.

Authors:  L L Thomsen; H K Iversen; T A Brinck; J Olesen
Journal:  Cephalalgia       Date:  1993-12       Impact factor: 6.292

View more
  9 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 3.  Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.

Authors:  Ann C Raddant; Andrew F Russo
Journal:  Expert Rev Mol Med       Date:  2011-11-29       Impact factor: 5.600

4.  Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.

Authors:  Sahar Z Swidan; Alvin E Lake; Joel R Saper
Journal:  Curr Pain Headache Rep       Date:  2005-02

Review 5.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

Review 6.  Cerebral hemodynamics in the different phases of migraine and cluster headache.

Authors:  Jakob M Hansen; Christoph J Schankin
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

Review 7.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 8.  The role of nitric oxide in vascular headache.

Authors:  Paul-Hugo M van der Kuy; Joseph J Lohman
Journal:  Pharm World Sci       Date:  2003-08

Review 9.  Human models of migraine - short-term pain for long-term gain.

Authors:  Messoud Ashina; Jakob Møller Hansen; Bára Oladóttir Á Dunga; Jes Olesen
Journal:  Nat Rev Neurol       Date:  2017-10-06       Impact factor: 42.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.